首页AIM • NYSEAMERICAN
add
AIM ImmunoTech Inc
相关资讯
财务信息
损益表
收入
净收入
| (USD) | 2025年3月info | 年同比变化 |
|---|---|---|
收入 | 1.60万 | -60.00% |
经营支出 | 362.50万 | -37.13% |
净收入 | -370.50万 | 36.31% |
净利润率 | -2.32万 | -59.23% |
每股收益 | -5.00 | 58.33% |
息税折旧摊销前利润 | -356.10万 | 37.26% |
有效税率 | — | — |
资产负债表
总资产
负债总额
| (USD) | 2025年3月info | 年同比变化 |
|---|---|---|
现金及短期投资 | 224.70万 | -79.46% |
总资产 | 624.80万 | -61.41% |
负债总额 | 1010.50万 | -11.07% |
权益总额 | -385.70万 | — |
发行在外的股份 | 76.42万 | — |
市净率 | -1.65 | — |
资产回报率 | -121.80% | — |
资本回报率 | -6,371.48% | — |
现金流
现金净变动
| (USD) | 2025年3月info | 年同比变化 |
|---|---|---|
净收入 | -370.50万 | 36.31% |
来自运营的现金 | -236.10万 | 50.97% |
投资现金 | 89.80万 | 668.35% |
融资现金 | 66.00万 | -76.67% |
现金净变动 | -80.30万 | 62.55% |
自由现金流 | -175.74万 | 36.37% |
简介
AIM ImmunoTech Inc., formerly known as Hemispherx Biopharma Inc., is a biopharmaceutical company based in Ocala, Florida that is focused on the research and development of therapeutics to treat multiple types of cancers, various viruses and immune-deficiency disorders. Founded in 1990, the company has twenty-three employees.
The company has created an immunomodulatory double stranded RNA drug called Ampligen.
It is also developing Ampligen to use as a treatment for multiple cancer tumor types, COVID-19 and chronic fatigue syndrome. Wikipedia
成立时间
1966
员工数量
22
